t
IXICO plc's General Meeting, held on 25 October 2024, saw shareholders pass all resolutions related to a placing, subscription, and retail offer. Following this approval, the company allotted a total of 42,621,508 new ordinary shares, consisting of 41,315,792 from the Placing, 516,244 from the Retail Offer, and 789,472 from the Subscription. Admission of these shares is expected on or around 28 October 2024, after which the total number of ordinary shares in issue will be 92,668,598.
| Date | 25 Oct 2024 |
| Time | 12:55:06 |
| Category | Capital structure |
| ID | 7236J |
25 October 2024
IXICO PLC
("IXICO" or the "Company")
Result of General Meeting, Issue of Equity and Total Voting Rights
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, announces that all resolutions put to Shareholders at the General Meeting held earlier today in connection with the placing, subscription and retail offer announced by the Company on 8 October 2024 were duly passed, including the amendment resolutions referred to in the announcement dated 22 October 2024.
|
Resolution |
For |
Against |
Withheld |
Total votes cast |
|||
|
|
|
Number of votes |
% |
Number of votes |
% |
Number of votes |
|
|
1 |
Ordinary resolution to authorise the directors to allot shares |
26,857,594 |
99.97% |
8,194 |
0.03% |
37,912 |
26,865,788 |
|
2 |
Ordinary resolution to approve the Company's EMI Share Option Plan |
26,676,840 |
99.30% |
188,448 |
0.70% |
38,412 |
26,865,288 |
|
3 |
Special resolution to authorise the directors to disapply pre-emption rights |
26,827,687 |
99.86% |
38,101 |
0.14% |
37,912 |
26,865,788 |
(1) Any proxy appointments, which gave discretion to the Chairman have been included in the "For" votes total.
(2) Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.
(3) A vote "Withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against", nor in the aggregate figure of total votes cast.
Issue of Equity and Total Voting Rights
Following shareholder approval at the general meeting and conditional on admission, 41,315,792 new ordinary shares have been allotted pursuant to the Placing, 516,244 new ordinary shares pursuant to the Retail Offer and 789,472 pursuant to the Subscription.
The Company has therefore allotted a total of 42,621,508 new ordinary shares in connection with the Fundraising.
Admission is expected to take place at 8.00 a.m. on or around 28 October 2024.
Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 92,668,598 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 92,668,598.
The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in the announcement of the Placing and Subscription dated 8 October 2024, unless otherwise defined in this announcement.
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer |
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated adviser and sole broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny / Dan Hodkinson (Corporate Finance) |
|
|
Nigel Birks (Life Sciences Specialist Sales) |
|
|
Harriet Ward (Corporate Broking) |
|
|
Michael F Johnson / Tamar Cranford Smith (Sales) |
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on X (formerly Twitter) @IXICOnews